Cannabis induces a clinical response in patients with crohn's disease: A prospective placebo-controlled study

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 10, 2013, Pages

  Naftali, Timna ^a   Bar Lev Schleider, Lihi ^b   Dotan, Iris ^c   Lansky, Ephraim Philip ^d   Sklerovsky Benjaminov, Fabiana ^a   Konikoff, Fred Meir ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b Tikun Olam for Promotion of Medical Cannabis   (Israel)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^d UNIVERSITY OF HAIFA   (Israel)

Author keywords

Cannabinoids; Crohn's Disease; Endocannabinoid; Inflammation; Inflammatory Bowel Disease

Indexed keywords

DRONABINOL; IMMUNOMODULATING AGENT; MESALAZINE; METHOTREXATE; PLACEBO; PREDNISONE; PURINE DERIVATIVE; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ABDOMINAL PAIN; ADULT; AMNESIA; APPETITE; ARTICLE; CANNABIS SMOKING; CLINICAL ARTICLE; CONFUSION; CONTROLLED STUDY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISEASE ACTIVITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FLOWER; HUMAN; LABORATORY TEST; MALE; NAUSEA; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; SATISFACTION; SHORT FORM 36; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; TREATMENT RESPONSE;

C-REACTIVE PROTEIN; CANNABIDIOL; CANNABINOIDS; CBD; CDAI; CROHN'S DISEASE; CROHN'S DISEASE ACTIVITY INDEX; CRP; ENDOCANNABINOID; IBD; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; SF-36; SHORT-FORM 36; THC; TNF; TUMOR NECROSIS FACTOR; Δ9-TETRAHYDROCANNABINOL;

ADULT; CANNABINOIDS; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MALE; MIDDLE AGED; PLACEBOS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84884302067     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.04.034     Document Type: Article

References (19)

1. Hall W., Solowij N. Adverse effects of cannabis. Lancet 1998, 352:1611-1616.
2. Nahas G., Sucui-Foca N., Armand J.P. Decrease of cellular immunity in hashish (marihuana) smokers. CR Acad Sci Hebd Seances Acad Sci D 1973, 277:979-980.
3. Sofia R.D., Knobloch L.C., Vassar H.B. The anti-edema activity of various naturally occurring cannabinoids. Res Commun Chem Pathol Pharmacol 1973, 6:909-918.
4. Pacifici R., Zuccaro P., Pichini S., et al. Modulation of the immune system in cannabis users. JAMA 2003, 289:1929-1931.
5. Small-Howard A.L., Shimoda L.M., Adra C.N., et al. Anti-inflammatory potential of CB1-mediated cAMP elevation in mast cells. Biochem J 2005, 25:25.
6. Berdyshev E.V. Cannabinoid receptors and the regulation of immune response. Chem Phys Lipids 2000, 108:169-190.
7. Izzo A.A., Camilleri M. Gastrointestinal and liver diseases: basic and clinical aspects: emerging role of cannabinoids. Gut 2008, 57:1140-1155.
8. Storr M.A., Keenan C.M., Zhang H., et al. Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. Inflamm Bowel Dis 2009, 11:1678-1685.
9. Borrelli F., Aviello G., Romano B., et al. Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis. Mol Med 2009, 87:1111-1121.
10. Jamontt J.M., Molleman A., Pertwee R.G., et al. The effects of D9-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and invitro motility disturbances in rat colitis. Br J Pharmacol 2010, 160:712-723.
11. Naftali T., Bar Lev L., Yablekovitch D., et al. Treatment of Crohn's disease with cannabis: an observational study. Isr Med Assoc J 2011, 13:455-458.
12. Altman D.G., Bland J.M. How to randomise. BMJ 1999, 319:703-704.
13. Diagnostic and statistical manual of mental disorders 1994, 215-223. American Psychiatric Association, American Psychiatric Association, Washington, DC. 4th ed.
14. Greineisen W.E., Turner H. Immunoactive effects of cannabinoids: considerations for the therapeutic use of cannabinoid receptor agonists and antagonists. Int Immunopharmacol 2010, 10:547-555.
15. Williamson E.M., Evans F.J. Cannabinoids in clinical practice. Drugs 2000, 60:1303-1314.
16. Schon F., Hart P., Hodgson T.R., et al. Suppression of pendular nystagmus by cannabis in a patient with multiple sclerosis. Neurology 1999, 53:2209-2210.
17. Gurley R.J., Aranow R., Katz M. Medicinal marijuana: a review. JPsychoactive Drugs 1998, 30:137-147.
18. Wang T., Collet J.P., Shapiro S., et al. Adverse effects of medical cannabinoids: a systematic review. CMAJ 2008, 178:1669-1678.
19. Jones R.T., Benowitz N., Bachman J. Clinical studies of cannabis tolerance and dependence. Ann N Y Acad Sci 1976, 282:221-239.